Clinical updates for metastatic hormone sensitive prostate cancer at ASCO 2019

Prostate Cancer Conference Highlights from ASCO GU 2023Подробнее

Update on ARCHES trial: implications for prostate cancer treatmentПодробнее

Dr. Sweeney on the Phase III ENZAMET Trial in Metastatic Hormone-Sensitive Prostate CancerПодробнее

Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancerПодробнее

ASCO GU 2019 - Dr. Andrew J. Armstrong, Duke University, NC, USAПодробнее

Prostate Cancer Conference Highlights from ASCO 2022Подробнее

Interview with Prof. Armstrong at ASCO GU 2019Подробнее

Prostate cancer updates: TITAN and ENZAMETПодробнее

ASCO GU 2019: treatment and management of hormone-sensitive metastatic prostate cancerПодробнее

Updates on Management of Metastatic Hormone-Sensitive Prostate CancerПодробнее

Triplet Therapy for Metastatic Hormone-sensitive Prostate CancerПодробнее

Evaluating Significance of ENZAMET Trial in Metastatic Hormone-Sensitive Prostate CancerПодробнее

Treatment landscape for metastatic hormone-sensitive prostate cancerПодробнее

Prostate cancer: treatment sequencing and choiceПодробнее

ARCHES trial overview: ADT plus enzalutamide for metastatic hormone-sensitive prostate cancerПодробнее

Developments in metastatic hormone-sensitive prostate cancerПодробнее

Metastatic castration resistant prostate cancer: Updates from ASCO 2019Подробнее

Systemic triple therapy in metastatic hormone-sensitive prostate cancerПодробнее

Update on the ARCHES Trial: New Indication for Enzalutamide in mHSPCПодробнее

Axel Merseburger, ESMO 2019 - Advances in metastatic hormone-sensitive prostate cancerПодробнее

Updates on Management of Metastatic Hormone-Sensitive Prostate CancerПодробнее